- Europe's stock indices face slight declines
- Novartis to acquire MorphoSys for €2.7 billion with a price of €68 per share
- Stifel lowered its recommendation for RWE shares
European stock indices are marginally losing during Tuesday's trading session. Despite gains in China's indices after new rumors suggesting the implementation of broad solutions to support the economy, the better mood does not carry over to the Old Continent. Individual benchmarks cannot find a common direction. In Germany alone, attention is once again turning to MorphoSys, whose shares are gaining another 15% after the announcement of Novartis' €2.7 billion takeover bid for the company.
Start investing today or test a free demo
Create account Try a demo Download mobile app Download mobile appSource: xStation5
DAX (DE40) futures are trading down moderately today and are currently trading in the zone of a key support barrier, marked by the local lows of the consolidation zone initiated in early January and the 50-day exponential moving average (blue curve).
News
MorphoSys (MOR.DE) shares are continuing their strong gains after Novartis (NOVN.CH) agreed to buy MorphoSys AG for €2.7 billion. The Swiss drugmaker will pay 68 euros per share for the German cancer drug maker, which is 61% above the February 2 closing price. The company's shares have gained nearly 56% since yesterday's session.
Source: xStation
Aurubis (NDA.DE) shares are gaining nearly 1.11% in today's session, after reporting worse-than-expected quarterly results and better annual forecasts. Analysts comment, however, that the announced restructuring of the Board of Directors is a factor of uncertainty.
FIRST QUARTER RESULTS
- Operating profit before tax €111 million, estimates €118.5 million
- Operating return on invested capital +9.7%
- Operating income €3.90 billion
- Operating profit €111 million, forecast €120.3 million
ANNUAL FORECAST
- Still sees operating return on invested capital in the range of +10% to +14%
COMMENTARY AND CONTEXT
- Operating EBT is expected to be in the range of €380 million to €480 million in the current fiscal year 2023/24.
- The implementation of the growth strategy will continue uninterrupted in the current fiscal year, despite the restructuring of the Board of Directors.
Analyst action
- HSBC downgraded its recommendation for Metro AG (B4B.DE) shares to a "reduce" rating (previously it was "hold"). The target price was set at €5.5 per share.
- Stifel downgraded its recommendation for shares of RWE (RWE.DE) to a "hold" rating from the previous "buy." The broker sees 2024 as a challenging year due to energy prices in Europe and the flow of political news in the US.
The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.
